Brigatinib Tablet Market Size, Share, Growth, And Industry Analysis by Type (30mg, 50mg, 180mg) by Application (Hospital, Pharmacy), Regional Insights and Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

BRIGATINIB TABLET MARKET OVERVIEW

The global brigatinib tablet market size was valued at USD 0.19 billion in 2024 and is projected to touch USD 0.35 billion by 2033, at a CAGR of 7% during the forecast period from 2025 To 2033.

Brigatinib tablet, delivered to the market for treating anaplastic lymphoma kinase (ALK)-positive non-small mobile lung most cancers (NSCLC), have revolutionized targeted cancer therapy. Approved through the FDA in 2017, brigatinib, advertised underneath the brand call Alunbrig, addresses sufferers proof against or illiberal of crizotinib, the preceding fashionable treatment. Its launch presented new wish due to its excessive efficacy and advanced development-free survival fees. Brigatinib's unique potential to penetrate the mind and goal ALK mutations makes it a crucial alternative for patients with mind metastases. The market advent changed into sponsored by way of sturdy scientific trials demonstrating massive tumor discount and potential side consequences. With its compelling scientific profile, brigatinib has been rapidly followed in oncology practices worldwide, solidifying its function as an essential player within the landscape of ALK-nice NSCLC treatments.

COVID-19 IMPACT

Pandemic Notably Hindered the Market Due to Shortages of Raw Materials and Delayed Manufacturing and Distribution Processes

The COVID-19 pandemic has been unprecedented and staggering, with brigatinib tablet market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels once the pandemic is over.

The COVID-19 pandemic negatively impacted the brigatinib tablet market growth in several approaches. Disruptions in global supply chains brought about shortages of raw materials and behind schedule production and distribution strategies. Many healthcare structures, crushed by using COVID-19 instances, deprioritized non-COVID treatments, resulting in decreased prognosis and treatment of cancers, including the ones treated with brigatinib. Clinical trials for brigatinib confronted interruptions, delaying ongoing studies and the approval of new indications. Patients skilled problems getting access to healthcare facilities because of lockdowns and fear of infection, leading to decreased prescription quotes. Additionally, monetary downturns affected patients' potential to have enough money steeply-priced treatments. These elements collectively hindered the growth and accessibility of brigatinib, impacting its market overall performance for the duration of the pandemic. Despite those challenges, efforts to adapt to the new regular, inclusive of telemedicine and revised medical trial protocols, had been carried out to mitigate some of the bad affects.

LATEST TRENDS

Rising Adoption of Personalized Medicine Helps Market to Grow

One latest trend inside the brigatinib tablet market is the increasing adoption of personalized medication. Personalized medicinal drug, which tailors remedy based on character genetic profiles, has gained giant traction in oncology. Brigatinib, with its efficacy in treating ALK-wonderful non-small mobile lung most cancers (NSCLC), exemplifies this trend. As genetic checking out will become more available and less costly, identifying patients with genetic mutations like ALK has grown to be less difficult. This precise concentrated on no longer simplest improves treatment consequences however additionally minimizes side consequences, making treatments like brigatinib more attractive. The shift towards customized medicinal drug is driving the call for centered treatment options, bolstering brigatinib's market position and paving the way for in addition improvements in cancer remedy.

Request a Free sample to learn more about this report

BRIGATINIB TABLET MARKET SEGMENTATION

By Type

Depending on brigatinib tablet market given are types 30mg, 50mg, 180mg. 

• 30mg: Typically used at some stage in the initial segment of remedy to reduce aspect consequences, permitting sufferers to step by step modify to the medicine. They offer a lower dosage alternative for sufferers requiring a tailored healing method.

• 180mg: Often prescribed for maintenance therapy or dose changes, imparting flexibility in handling patient-unique responses and aspect outcomes. This dosage enables optimize treatment effectiveness while retaining tolerability.

• 180mg: Usually, the standard dosage for complete therapeutic impact in treating ALK-high-quality NSCLC. This better dosage objectives to supply maximum efficacy for sufferers who can tolerate it, imparting great scientific benefits in tumor discount and disorder control.

By Application

The market is divided into hospital, pharmacy.

• Hospital: Brigatinib tablet inside the hospital market are in the main used for inpatient care, where sufferers acquire direct clinical supervision and monitoring at some point of remedy initiation and control. Hospitals also play an important position in accomplishing clinical trials and managing complicated cases requiring specialized car.

• Pharmacy: In the pharmacy market, brigatinib tablet are disbursed for outpatient care, presenting patients with convenient access to their medication for domestic management. Pharmacies ensure ongoing medication supply, affected person schooling, and adherence assist, contributing to the continuity of care.

DRIVING FACTORS

Increasing Incidence of ALK-Positive Non-Small Cell Lung Cancer Drives the Market

The rising prevalence of ALK-high quality NSCLC is a great riding thing for the brigatinib tablet market. Advances in genetic testing and molecular diagnostics have progressed the identity of ALK mutations in NSCLC patients. Early and accurate detection of these mutations has increased the demand for targeted healing procedures like brigatinib, that is particularly designed to inhibit the ALK protein. As focus of ALK-tremendous NSCLC grows amongst healthcare experts and patients, the need for powerful, focused remedies continues to rise, bolstering the market for brigatinib tablet.

Advancements in Targeted Cancer Therapies Drives the Market

Advancements in centered cancer treatment options have notably pushed the brigatinib tablet market. Targeted therapies, like brigatinib, attention on genetic mutations and pathways worried in cancer growth, presenting more powerful and customized remedy options compared to standard chemotherapy. Ongoing studies and improvement on this area have led to the advent of subsequent-generation ALK inhibitors with stepped forward efficacy and safety profiles. These improvements no longer handiest enhance patient consequences however additionally increase the healing alternatives to be had to oncologists, fostering multiplied adoption and market boom for brigatinib tablet.

RESTRAINING FACTORS

Regulatory Challenges and Market Entry Barriers Restrains the Market Growth

One restraining factor in the brigatinib tablet market is regulatory challenges and market access obstacles. The stringent regulatory requirements for drug approval, particularly in extraordinary nations with varying approval timelines and criteria, can put off market access and restrict geographical enlargement. Additionally, navigating complicated regulatory landscapes, which include pricing and repayment rules, adds to the project of commercializing brigatinib efficaciously. These factors contribute to slower market penetration and adoption, despite the therapeutic advantages of brigatinib in treating ALK-positive NSCLC. Overcoming these boundaries requires strategic regulatory planning and partnerships to streamline approval approaches and ensure timely get entry to sufferers in want.

• Request a Free sample to learn more about this report

•  

BRIGATINIB TABLET MARKET REGIONAL INSIGHTS

Asia Pacific to Dominate the Market Due to Increasing Incidences of ALK-Positive Non-Small Cell Lung Cancer

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa

The Asia Pacific regional is poised to play a dominant function inside the brigatinib tablet market share. This growth is pushed with the aid of increasing incidences of ALK-high quality non-small mobile lung most cancers, enhancing healthcare infrastructure, and growing cognizance of targeted cures. Countries like China, Japan, and South Korea are widespread participants due to their huge patient populations and ongoing improvements in oncology research. Moreover, favorable government initiatives, increasing pharmaceutical markets, and a developing recognition on personalized medicine similarly help the region's potential as a key market for brigatinib drugs.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Key industry players in the brigatinib tablet market consist of pharmaceutical businesses focusing on oncology and centered remedies. Among them, Takeda Pharmaceutical Company with its product Alunbrig holds a prominent function. Other foremost gamers together with Pfizer Inc. And Novartis AG, known for their enormous portfolios in oncology treatments, also make contributions substantially to the market. These businesses are actively concerned in research and development, clinical trials, and strategic partnerships to beautify the accessibility and efficacy of brigatinib tablet for ALK-high-quality non-small mobile lung most cancers sufferers globally. Their expertise and market presence shape the competitive panorama of this specialized phase.

List of Top Brigatinib Tablet Companies

• Takeda (Japan)

INDUSTRIAL DEVELOPMENT

January 2022: An industrial development in the brigatinib tablet market is Takeda Pharmaceutical Company Limited said that it has received approval from the Japanese Ministry of health, labour, and welfare to produce and market the “ALUNBRIG® Tablets 30 mg, 90 mg”, the first- and second-line therapy for the treatment of the patients with unresectable, metastatic, or recurrent ALK fusion gene positive NSCLC.

REPORT COVERAGE 

The brigatinib tablet market affords a dynamic panorama pushed by improvements in targeted cancer treatment options and increasing incidences of ALK-high-quality non-small cellular lung cancer (NSCLC). Key industry gamers like Takeda Pharmaceutical Company, Pfizer Inc., and Novartis AG are pivotal in shaping market dynamics thru their enormous research, development efforts, and international market presence. Despite regulatory demanding situations and market entry barriers, mainly in pricing and repayment rules, the market keeps to amplify, fueled by rising attention and adoption of personalized medicinal drug. The Asia-Pacific region, led by countries inclusive of China and Japan, is rising as a good-sized market because of its developing healthcare infrastructure and affected person populace. Looking forward, improvements in ALK inhibitors, ongoing medical trials, and strategic collaborations are expected to further pressure market increase, imparting promising prospects for brigatinib tablet in improving outcomes for ALK-positive NSCLC sufferers international